Generating Anti-TIGIT and CD155 Monoclonal Antibodies for Tumor Immunotherapy

Abstract Many studies have confirmed that the human poliovirus receptor (PVR; CD155) is related to tumor cell migration, invasion, and thus progression. A PVR binds its ligand T Ig ITIM domain (TIGIT) inhibit function of NK cells, thereby allowing tumors evade immune surveillance. In this study, two IgG1 monoclonal antibodies, anti-CD155 anti-TIGIT, were expressed by mammalian transient transfection system, then, antibody-dependent cell-mediated cytotoxicity, antibody-binding affinity, antitumor efficacy evaluated subsequently in vitro. work, protein affinity chromatography was used for antibodies' purification. Analysis methods included Western blot, enzyme-linked immunosorbent assay, flow cytometry. Our data suggested both antibodies a purity higher than 90%, bound tightly antigen with dissociation constant (K d) 50% effective concentrations (EC50) below micromolar range. Most notably, these promote activity cells Therefore, our study laid down foundation subsequent vivo experiments further evaluation.